Business
Perimeter Medical Imaging AI to Present at the 13th Annual LD Micro Main Event Investor Conference
TORONTO, ON / ACCESSWIRE / December 11, 2020 / Perimeter Medical Imaging AI, Inc. (TSXV:PINK...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"Perimeter Medical Imaging AI to Present at the 13th Annual LD Micro Main Event Investor ConferenceTORONTO, ON / ACCESSWIRE / December 11, 2020 / Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(FSE:4PC), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need, announced today that Jeremy Sobotta, Perimeter's Chief Executive Officer, will present a corporate overview at the 13th Annual LD Micro Main Event (virtual) investor conference on Monday, December 14, 2020 at 12:40 pm ET.The Main Event will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform, and it features a new and unique format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts.LD Micro Main Event Conference December 14th and 15th, 2020Presentation Date: Monday, December 14, 2020Presentation Time: 12:40 pm Eastern TimeRegistration Link: https://ve.mysequire.com/The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the \"Investors\" section of Perimeter's website at: https://ir.perimetermed.com/About Perimeter Medical Imaging AI, Inc. Perimeter Medical Imaging AI (TSXV:PINK; FSE:4PC) is a Toronto-based company with U.S. headquarters in Dallas, Texas that is developing, with plans to commercialize, advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during a clinical procedure. Perimeter's OTIS™ platform is a point-of-care imaging system that provides clinicians with real-time, ultra-high-resolution, sub-surface image volumes of the margin (1-2 mm below the surface) of an excised tissue specimen. The ability to visualize microscopic tissue structures during a clinical procedure in addition to standard of care tissue assessment for decision making during the procedure has the potential to result in better long-term outcomes for patients and lower costs to the healthcare system. Perimeter's OTIS™ platform is cleared by FDA as an imaging tool in the evaluation of excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization, with image review manipulation software for identi...